期刊文献+

盐酸莫西沙星片的人体药动学研究 被引量:16

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers
原文传递
导出
摘要 目的:研究盐酸莫西沙星片在我国健康人体内的药动学。方法:12名健康受试者单剂量口服盐酸莫西沙星片400mg后,采用高效液相色谱-紫外(HPLC-UV)法检测人血浆中莫西沙星的浓度,用DAS软件进行数据处理,采用非房室模型法评估药动学参数。结果:单剂量口服莫西沙星片400mg后,主要药动学参数分别为:AUC0~2(432.57±6.94)mg·h·L-1,AUC0~∞(40.55±8.71)mg·h·L-1,Cmax(3.06±0.42)mg·L-1,tmax(1.75±0.76)h,t1/(210.32±1.98)h,MRT0~2(48.55±0.30)h,MRT0~∞(14.59±2.32)h,V(d150.62±34.00)L,CLz/F(10.20±1.77)L·h-1。除2例有可耐受的胃肠道不适外,无明显不良反应发生。结论:建立的HPLC-UV法可用于莫西沙星药动学研究。我国健康志愿者口服莫西沙星具血药峰浓度高、半衰期长、耐受性好的特点,与国外人体药动学参数基本一致。 OBJECTIVE: To study the pharmacokinetics of moxifloxacin hydrochloride tablet in healthy volunteers. METHODS: 12 healthy volunteers were orally administered with a single dose of 400 mg moxifloxacin hydrochloride tablet. The plasma concentrations of moxifloxacin in human plasma were measured by HPLC-UV method. The data were processed with DAS software and non-compartment model was used to evaluate pharmacokinetic parameters. RESULTS: After giving single dose of 400 mg moxifloxacin hydrochloride tablet, main pharmacokinetic parameters were as follows: AUC0-24(32.57±6.94)mg·h·L^-1,AUC0-∞(40.55±8.71)mg·h·L^-1,Cmax(3.06±0.42)mg·L^-1,tmax(1.75±0.76)h,t1/2(10.32±1.98)h,MRT0-24(8.55±0.30)h,MRT0-∞(14.59±2.32)h,Vd(150.62±34.00)L,CL2/F(10.20±1.77)L·h^-1. No significant ADR was observed, except for tolerable gastrointestinal discomfort in 2 cases. CONCLUSION: The established HPLC-UV method could be used for the pharmacokinetic study of moxifloxacin. Moxifloxacin after oral administration is well tolerable in Chinese healthy volunteers and its pharmacokinetics was characterized with high peak concentration and long half-life. The pharmacokinetic parameters obtained from Chinese healthy volunteers are accordant with those from foreign populations.
出处 《中国药房》 CAS CSCD 北大核心 2010年第10期898-901,共4页 China Pharmacy
基金 深圳市科技计划(卫生医疗类)项目(200703224 200803147)
关键词 高效液相色谱-紫外法 莫西沙星 血药浓度 药动学 HPLC-UV Moxicifloxacin Plasma concentration Pharmacokinetics
  • 相关文献

参考文献10

  • 1Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections[J].Drugs, 2004, 64 (20) : 2 347.
  • 2Julia A, Balfour B, Wiseman LR. Moxifloxacin[J]. Drugs, 1999,57 (3) : 363.
  • 3Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifioxacin[J]. Clin Infect Dis,2001,32 (Suppl 1) :51.
  • 4Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokineties of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone[J]. Antimicrob Agents Chemother, 1999, 43 (11 ) : 2 793.
  • 5Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man [J]. JAntimicrob Chemother, 1999, 43 (Suppl) : 83.
  • 6Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction[J]. Br J Clin Pharmacol, 2002, 53 (3):232.
  • 7Sullivan JT, Lettieri JT, Liu P, et al. The influence of age and gender on the pharmacokinetics of moxifloxacin[J]. Clinical Pharmacokinetics, 2001,40 ( Suppl 1 ) : 11.
  • 8Lettieri J, Vargas R, Agarwal V, et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers[J]. Clin Pharmacokinet, 2001, 40 (Suppl 1 ) : 19.
  • 9Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers [J]. Clin Pharmacokinet, 2001,40 (Suppl 1 ) : 33.
  • 10Laban-Djurdjevic A, Jelikic-Stankov M, Djurdjevic P. Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, 844 (1): 104.

同被引文献81

引证文献16

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部